The fiscal quarter ended 31 December was mostly successful for six major Japanese firms, with Daiichi Sankyo Co., Ltd. in particular showing good revenue growth on the back of its blockbuster antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan).
Japan Q3 Roundup: Daiichi Emerges As Growth Leader While Others Balance Ups And Downs
The success of Enhertu led Daiichi Sankyo to raise its annual forecast for the fiscal year ending 31 March, while Eisai is readying for Leqembi’s steady US growth. Meanwhile, Astellas, Chugai and Shionogi balanced growth for some products with declines for others.
